{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:37:27Z","timestamp":1789616247590,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Key Program of National Natural Science Foundation of China","award":["U23A20465"],"award-info":[{"award-number":["U23A20465"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402331"],"award-info":[{"award-number":["82402331"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272035"],"award-info":[{"award-number":["82272035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Scientific and Technological Innovation Program","award":["23DZ2291400"],"award-info":[{"award-number":["23DZ2291400"]}]},{"name":"Shanghai Scientific and Technological Innovation Program","award":["23TS1400800"],"award-info":[{"award-number":["23TS1400800"]}]},{"name":"Shanghai Anticancer Association Program","award":["SACA-AX202316"],"award-info":[{"award-number":["SACA-AX202316"]}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"crossref","award":["SHDC 12023103"],"award-info":[{"award-number":["SHDC 12023103"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07609-0","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T06:29:41Z","timestamp":1761287381000},"page":"2362-2374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A pilot study of nectin-4-targeted radioligand [68Ga]Ga-FZNR-1 in patients with pancreatic ductal adenocarcinoma: head-to-head comparison with [18F]-FDG"],"prefix":"10.1007","volume":"53","author":[{"given":"Chunjuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoyan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-7522","authenticated-orcid":false,"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"7609_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"7609_CR2","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s00259-021-05216-3","volume":"48","author":"M Li","year":"2021","unstructured":"Li M, Wei W, Barnhart TE, Jiang D, Cao T, Fan K, et al. ImmunoPET\/NIRF\/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2021;48:2737\u201348. https:\/\/doi.org\/10.1007\/s00259-021-05216-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7609_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3348\/kjr.2019.0862","volume":"22","author":"H Rhee","year":"2021","unstructured":"Rhee H, Park MS. The role of imaging in current treatment strategies for pancreatic adenocarcinoma. Korean J Radiol. 2021;22:23\u201340. https:\/\/doi.org\/10.3348\/kjr.2019.0862.","journal-title":"Korean J Radiol"},{"key":"7609_CR4","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.3748\/wjg.v19.i29.4808","volume":"19","author":"Z Wang","year":"2013","unstructured":"Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y. FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol. 2013;19:4808\u201317. https:\/\/doi.org\/10.3748\/wjg.v19.i29.4808.","journal-title":"World J Gastroenterol"},{"key":"7609_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2967\/jnumed.123.266393","volume":"65","author":"AM Spektor","year":"2024","unstructured":"Spektor AM, Gutjahr E, Lang M, Glatting FM, Hackert T, Pausch T, et al. Immunohistochemical FAP expression reflects (68)Ga-FAPI PET imaging properties of low- and high-grade intraductal papillary mucinous neoplasms and pancreatic ductal adenocarcinoma. J Nucl Med. 2024;65:52\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.266393.","journal-title":"J Nucl Med"},{"key":"7609_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","volume":"21","author":"W Bouleftour","year":"2022","unstructured":"Bouleftour W, Guillot A, Magne N. The anti-Nectin 4: a promising tumor cells target. A systematic review. Mol Cancer Ther. 2022;21:493\u2013501. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0846.","journal-title":"Mol Cancer Ther"},{"key":"7609_CR7","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76:3003\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1313.","journal-title":"Cancer Res"},{"key":"7609_CR8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/annonc\/mdw678","volume":"28","author":"MMR Cabaud","year":"2017","unstructured":"Cabaud MMR, Josselin O, Finetti E, Castellano P, Farina R. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol. 2017;28:769\u201376. https:\/\/doi.org\/10.1093\/annonc\/mdw678.","journal-title":"Ann Oncol"},{"key":"7609_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13046-015-0144-7","volume":"34","author":"S Nishiwada","year":"2015","unstructured":"Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, et al. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res. 2015;34:30. https:\/\/doi.org\/10.1186\/s13046-015-0144-7.","journal-title":"J Exp Clin Cancer Res"},{"key":"7609_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-019-0824-z","volume":"19","author":"H Deng","year":"2019","unstructured":"Deng H, Shi H, Chen L, Zhou Y, Jiang J. Over-expression of Nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients. Cancer Cell Int. 2019;19:106. https:\/\/doi.org\/10.1186\/s12935-019-0824-z.","journal-title":"Cancer Cell Int"},{"key":"7609_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2967\/jnumed.124.269024","volume":"66","author":"L Sun","year":"2025","unstructured":"Sun L, Sun Y, Zuo K, Fan L, Wang X, Zhang J, et al. Pilot study of Nectin-4-targeted PET imaging agent (68)Ga-FZ-NR-1 in triple-negative breast cancer from bench to first-in-human. J Nucl Med. 2025;66:473\u20139. https:\/\/doi.org\/10.2967\/jnumed.124.269024.","journal-title":"J Nucl Med"},{"key":"7609_CR12","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","volume":"29","author":"X Duan","year":"2023","unstructured":"Duan X, Xia L, Zhang Z, Ren Y, Pomper MG, Rowe SP, et al. First-in-human study of the radioligand 68Ga-N188 targeting Nectin-4 for PET\/CT imaging of advanced urothelial carcinoma. Clin Cancer Res. 2023;29:3395\u2013407. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0609.","journal-title":"Clin Cancer Res"},{"key":"7609_CR13","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.2967\/jnumed.123.266830","volume":"65","author":"J Zhang","year":"2024","unstructured":"Zhang J, Duan X, Chen X, Zhang Z, Sun H, Shou J, et al. Translational PET imaging of Nectin-4 expression in multiple different cancers with (68)Ga-N188. J Nucl Med. 2024;65:S12\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.266830.","journal-title":"J Nucl Med"},{"key":"7609_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07402-z","author":"W Huang","year":"2025","unstructured":"Huang W, Sun X, Li X, Hsu JC, Qiu Y, DeLuca MC, et al. Rapid and specific ImmunoPET imaging of Nectin-4 in gastric cancer and non-small cell lung cancer using [64Cu]Cu-NOTA-EV-F(ab\u2019)2. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07402-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7609_CR15","doi-asserted-by":"publisher","first-page":"1081655","DOI":"10.3389\/fonc.2023.1081655","volume":"13","author":"R Liu","year":"2023","unstructured":"Liu R, Zhao K, Wang K, Zhang L, Ma W, Qiu Z, et al. Prognostic value of nectin-4 in human cancers: A meta-analysis. Front Oncol. 2023;13:1081655. https:\/\/doi.org\/10.3389\/fonc.2023.1081655.","journal-title":"Front Oncol"},{"key":"7609_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","volume":"18","author":"EI Heath","year":"2021","unstructured":"Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol. 2021;18:93\u2013103. https:\/\/doi.org\/10.1038\/s41585-020-00394-5.","journal-title":"Nat Rev Urol"},{"key":"7609_CR17","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/art.38690","volume":"66","author":"L Fardet","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613\u201320. https:\/\/doi.org\/10.1002\/art.38690.","journal-title":"Arthritis Rheumatol"},{"key":"7609_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/ajcp\/aqw076","volume":"145","author":"F Debaugnies","year":"2016","unstructured":"Debaugnies F, Mahadeb B, Ferster A, Meuleman N, Rozen L, Demulder A, et al. Performances of the H-score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients. Am J Clin Pathol. 2016;145:862\u201370. https:\/\/doi.org\/10.1093\/ajcp\/aqw076.","journal-title":"Am J Clin Pathol"},{"key":"7609_CR19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/his.12662","volume":"67","author":"E Specht","year":"2015","unstructured":"Specht E, Kaemmerer D, Sanger J, Wirtz RM, Schulz S, Lupp A. Comparison of immunoreactive score, HER2\/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms. Histopathology. 2015;67:368\u201377. https:\/\/doi.org\/10.1111\/his.12662.","journal-title":"Histopathology"},{"key":"7609_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/ACP-2011-014","volume":"34","author":"WE Pierceall","year":"2011","unstructured":"Pierceall WE, Wolfe M, Suschak J, Chang H, Chen Y, Sprott KM, et al. Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic response diagnostics. Anal Cell Pathol (Amst). 2011;34:159\u201368. https:\/\/doi.org\/10.3233\/ACP-2011-014.","journal-title":"Anal Cell Pathol (Amst)"},{"key":"7609_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00262-024-03861-9","volume":"74","author":"Y Ozawa","year":"2024","unstructured":"Ozawa Y, Koh Y, Shibaki R, Harutani Y, Akamatsu H, Hayata A, et al. Uncovering the role of tumor cGAS expression in predicting response to PD-1\/L1 inhibitors in non-small cell lung cancer. Cancer Immunol Immunother. 2024;74:7. https:\/\/doi.org\/10.1007\/s00262-024-03861-9.","journal-title":"Cancer Immunol Immunother"},{"key":"7609_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/RLU.0000000000001098","volume":"41","author":"JM Pimiento","year":"2016","unstructured":"Pimiento JM, Davis-Yadley AH, Kim RD, Chen DT, Eikman EA, Berman CG, et al. Metabolic activity by 18F-FDG-PET\/CT is prognostic for stage I and II pancreatic cancer. Clin Nucl Med. 2016;41:177\u201381. https:\/\/doi.org\/10.1097\/RLU.0000000000001098.","journal-title":"Clin Nucl Med"},{"key":"7609_CR23","doi-asserted-by":"publisher","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. Gastroenterology. 2022;163:386\u2013402 e1. https:\/\/doi.org\/10.1053\/j.gastro.2022.03.056","DOI":"10.1053\/j.gastro.2022.03.056"},{"key":"7609_CR24","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2967\/jnumed.123.265486","volume":"64","author":"T Watabe","year":"2023","unstructured":"Watabe T, Naka S, Tatsumi M, Kamiya T, Kimura T, Shintani Y, et al. Initial evaluation of [(18)F]FAPI-74 PET for various histopathologically confirmed cancers and benign lesions. J Nucl Med. 2023;64:1225\u201331. https:\/\/doi.org\/10.2967\/jnumed.123.265486.","journal-title":"J Nucl Med"},{"key":"7609_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3748\/wjg.v17.i7.867","volume":"17","author":"C Sharma","year":"2011","unstructured":"Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990\u20132010. World J Gastroenterol. 2011;17:867\u201397. https:\/\/doi.org\/10.3748\/wjg.v17.i7.867.","journal-title":"World J Gastroenterol"},{"key":"7609_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(10)62307-0.","journal-title":"Lancet"},{"key":"7609_CR27","doi-asserted-by":"publisher","unstructured":"Zhang J, Liu R, Wang S, Feng Z, Yang H, Gao S, et al. 9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase I\/II study. Ann Oncol. 2025. https:\/\/doi.org\/10.1016\/j.annonc.2025.04.009.","DOI":"10.1016\/j.annonc.2025.04.009"},{"key":"7609_CR28","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2035807.","journal-title":"N Engl J Med"},{"key":"7609_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41419-024-06665-y","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Nan Y, Ma C, Lu X, Wang Q, Huang X, et al. A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE. Cell Death Dis. 2024;15:293. https:\/\/doi.org\/10.1038\/s41419-024-06665-y.","journal-title":"Cell Death Dis"},{"key":"7609_CR30","doi-asserted-by":"publisher","unstructured":"Fu R, Wang C, Yin T, Zhang X, Xu Y, Shi Y, et al. A novel and promising therapeutic approach for treating pancreatic cancer: Nectin\u20134\u2013targeted antibody\u2013drug conjugates alone or combined with autophagy inhibitors. Int J Mol Med. 2025;55. https:\/\/doi.org\/10.3892\/ijmm.2025.5507.","DOI":"10.3892\/ijmm.2025.5507"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07609-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:39:00Z","timestamp":1771479540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07609-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7609"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07609-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Committee at Fudan University Shanghai Cancer Center (Ethical approval number: 2407299-29) conducted in accordance with 1964 Helsinki declaration and its amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from each patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors declare that there are no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}